A recent study documents increased SGK1 expression in a subset of breast cancer cell lines that are resistant to Akt inhibition, and treatment of these cells with an ATP-competitive mTOR kinase inhibitor leads to inhibition of SGK1 activation and suppression of proliferation, thus highlighting the role of SGK1 activation in breast cancer [38]. Here, AKT1 is linked to breast cancer.